Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients
Por:
Rosado-Sánchez I, Rodríguez-Gallego E, Peraire J, Viladés C, Herrero P, Fanjul F, Gutiérrez F, Bernal E, Pelazas R, Leal M, Veloso S, López-Dupla M, Blanco J, Vidal F, Pacheco YM and Rull A
Publicada:
30 abr 2019
Categoría:
Medicine (miscellaneous)
Resumen:
The immunological, biochemical and molecular mechanisms associated with poor immune recovery are far from known, and metabolomic profiling offers additional value to traditional soluble markers. Here, we present novel and relevant data that could contribute to better understanding of the molecular mechanisms preceding a discordant response and HIV progression under suppressive combined antiretroviral therapy (cART). Integrated data fromnuclear magnetic resonance (NMR)-based lipoprotein profiles, mass spectrometry (MS)-based metabolomics and soluble plasma biomarkers help to build prognostic and immunological progression tools that enable the differentiation of HIV-infected subjects based on their immune recovery status after 96 weeks of suppressive cART. The metabolomic signature of ART-naive HIV subjects with a subsequent late immune recovery is the expression of pro-inflammatory molecules and glutaminolysis, which is likely related to elevate T-cell turnover in these patients. The knowledge about how these metabolic pathways are interconnected and regulated provides new targets for future therapeutic interventions not only in HIV infection but also in other metabolic disorders such as human cancers where glutaminolysis is the alternative pathway for energy production in tumor cells to meet their requirement of rapid proliferation.
Filiaciones:
Rosado-Sánchez I:
Laboratory of Immunology, Institute of Biomedicine of Seville, IBiS, UGC Clinical Laboratories, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain
Rodríguez-Gallego E:
Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
Peraire J:
Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
Viladés C:
Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
Herrero P:
Eurecat, Centre Tecnològic de Catalunya, Unitat de Ciències Òmiques (Unitat Mixta de Eurecat- Universitat Rovira i Virgili), Infraestructura Científico-Tècnica Singular (ICTS), Reus, Spain
Fanjul F:
Department of Infectious Diseases, Hospital Universitario Son Espases, Palma de Mallorca, Illes Balears, Spain
:
Infectious Diseases Unit, Hospital General de Elche and Universidad Miguel Hernández, Alicante, Spain
Bernal E:
Department of Clinical Medicine, Universidad Católica San Antonio de Murcia and Hospital General Universitario Reina Sofía, Spain
Pelazas R:
Servicio de Medicina Interna, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain
Leal M:
Laboratory of Immunology, Institute of Biomedicine of Seville, IBiS, UGC Clinical Laboratories, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain
Internal Medicine Service, Viamed-Santa Ángela de la Cruz Hospital, Seville, Spain
Veloso S:
Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
López-Dupla M:
Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
Blanco J:
AIDS Research Institute IrsiCaixa, Institut Germans Trias I Pujol (IGTP)
Universitat Autònoma de Barcelona, Badalona, Spain
Universitat de Vic-Universitat Central de Catalunya, Vic, Spain
|